GMR Data have classified competitive activity as ‘high’ in the oncology sector and expect it to increase, being driven by the need for new therapeutics to meet the unmet needs of cancer patients. From a market worth an estimated $77.4bn, across 2013, GMR Data forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023.



Within GMR Data’s 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ we analyse the key cancer drugs and treatments on the market currently, and how they will perform across the next decade. 


GMR Data’s study focuses on the individual revenues of the top 25 anti-cancer agents; with variable patents and the threat of generics, how will the key cancer drugs fare across the next decade? You will also be able to access clear, concise details on cancer drugs that are coming to market or are near the end of the testing stages.


PLUS – In-depth country analysis – The report details which countries and regions will drive the oncology drugs market to 2023?

Exclusive Industry sourced information, not available anywhere else


As well as primary and secondary research sources, GMR Data have interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.


GMR Data’s 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’; can your company afford not to know what is happening in the cancer drugs sector across the next decade?



For further press details or to order a copy today

Please contact – Alice Morgan,

Ph; + 353 86 075 2687

Email :

or Online at